Published in
Elsevier, Annals of Oncology, (31), p. S1388-S1389, 2020
DOI: 10.1016/j.annonc.2020.10.373
Links
Tools
379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Journal article published in 2020 by
Jh H. Ji,
Jw W. Goldman,
Mc C. Garassino,
Y. Chen,
N. Reinmuth,
K. Hotta,
A. Poltoratskiy,
G. Statsenko,
O. Voitko,
D. Trukhin,
N. V. Conev,
Mj J. Hochmair,
I. Bondarenko,
S. Spencer,
M. Özgüroğlu 
and other authors.
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 